BioCentury
ARTICLE | Company News

MedImmune vanishes as AZ restructures, returns to growth

February 14, 2019 10:45 PM UTC

AstraZeneca plc (LSE:AZN; NYSE:AZN) recorded its first year of product sales growth since 2009 and unveiled a new R&D structure in its 2018 earnings report Thursday. With the restructuring, AZ will drop the MedImmune unit from its operations to integrate early and late stage drug development.

For the year, AZ reported product sales of $21 billion, up 4% from 2017. The company's shares climbed 7.5% in London and 9.3% on NYSE on Thursday...

BCIQ Company Profiles

AstraZeneca plc